Saxenda Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The saxenda market research report is one of a series of new reports that provides saxenda market statistics, including saxenda industry global market size, regional shares, competitors with saxenda market share, detailed saxenda market segments, market trends and opportunities, and any further data you may need to thrive in the saxenda industry. This saxenda market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast period can be attributed to growing personalized medicine, expanding healthcare infrastructure, rising demand for non-surgical weight loss solutions, and increasing use of digital health tools. Major trends in the forecast period include the emergence of combination therapies for weight loss, increasing availability of prescription weight loss medications, rising adoption of digital health and fitness apps, integration of weight management solutions into primary care, and greater focus on sustainable lifestyle changes.

The increasing prevalence of obesity is expected to drive the growth of the Saxenda market in the coming years. Obesity, which is characterized by excessive body fat, increases the risk of various health conditions such as diabetes, heart disease, and certain cancers. Factors contributing to the rising prevalence of obesity include poor diets, sedentary lifestyles, urbanization, genetic predispositions, and hormonal imbalances. Saxenda aids in combating obesity by regulating appetite through liraglutide, an active ingredient that mimics the natural hormone GLP-1, promoting feelings of fullness, reducing caloric intake, and supporting sustainable weight loss when combined with a healthy diet and regular exercise. For example, according to a May 2024 report by the Office for Health Improvement and Disparities (OHID), around 64% of adults in England were overweight or obese in 2022-2023, with 26.2% classified as obese. These figures were similar to those of the previous year, indicating a continued rise in obesity rates. This growing prevalence is expected to further drive demand for Saxenda.

The rising incidence of diabetes is also expected to boost the growth of the Saxenda market. Diabetes is a chronic condition that impairs the body's ability to regulate blood sugar levels, and its prevalence is rising due to unhealthy diets, sedentary lifestyles, obesity, aging populations, and genetic factors. Saxenda helps manage diabetes by leveraging liraglutide to improve insulin sensitivity, regulate blood sugar levels, and slow gastric emptying. This dual action supports both glycemic control and weight management. A report by Diabetes Canada in February 2023 indicated that nearly 30% of Ontario’s population, or about 2.4 million people, had diabetes or prediabetes, with a projected 25% increase in prevalence over the next decade. This rise is expected to drive up treatment costs from $1.7 billion to $2.1 billion annually by 2033, further contributing to the growth of the Saxenda market.

The trend fueling the Saxenda market is the development of generic products for weight management, which provide affordable alternatives to brand-name drugs. Generic medications are chemically identical to their branded counterparts, offering the same therapeutic effects but typically at a lower price. In April 2024, Biocon Limited, an India-based biopharmaceutical company, received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for its generic version of Saxenda, called Liraglutide (gSaxenda). This generic formulation, available as a 6 mg/ml solution in a pre-filled pen, is designed to aid in weight management when used alongside a reduced-calorie diet and increased physical activity. The approval of gSaxenda underscores the growing importance of cost-effective alternatives in addressing obesity, expanding the availability of treatment options and strengthening Biocon’s position in the market.

The key company operating in the saxenda market is Novo Nordisk

North America was the largest region in the saxenda market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in saxenda report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the saxenda market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Saxenda is a prescription medication containing liraglutide, designed to support weight management in adults with obesity or overweight conditions. It works by mimicking a natural hormone that regulates appetite, helping individuals reduce their caloric intake and achieve long-term weight loss when used alongside a reduced-calorie diet and increased physical activity.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main indications for Saxenda include obesity management (for individuals with a body mass index (BMI) of ≥30 kg/m²) and overweight management (for individuals with a BMI of ≥27 kg/m² to < 30 kg/m² who also have weight-related comorbidities). Obesity, defined as a BMI of 30 kg/m² or higher, is associated with an excess accumulation of body fat, significantly increasing the risk of chronic health issues such as type 2 diabetes, hypertension, and cardiovascular diseases. Saxenda is available in various forms, including injections and pre-filled pens, and is distributed through multiple channels such as hospital pharmacies, retail pharmacies, and online pharmacies. The end users include hospitals, clinics, and homecare settings.

The saxenda market consists of sales of products such as prefilled pens of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, and 3 mg. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.